SQZ Biotechnologies Co. (SQZ) News

SQZ Biotechnologies to effect 1-for-10 reverse stock split

• SQZ Biotechnologies (NYSE:SQZ) has approved a 1-for-10 reverse stock split of its common stock, effective on July 6, after market close.
• On the effective date, every 10 common shares issued and outstanding will be automatically combined into one share of common stock.
• The company ahs received notice from NYSE over not being compliant as average global market capitalization over a consecutive 30 day trading day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million.
• Source: Seeking Alpha | June 16, 2023

SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

WATERTOWN, Mass., June 15, 2023--SQZ Biotechnologies Company (NYSE: SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company’s common stock is expected to b

Yahoo | June 15, 2023

SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates

SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 10, 2023

SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., May 10, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates.

Yahoo | May 10, 2023

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 8, 2023

Investors Aren't Entirely Convinced By SQZ Biotechnologies Company's (NYSE:SQZ) Revenues

With a price-to-sales (or "P/S") ratio of 0.9x SQZ Biotechnologies Company ( NYSE:SQZ ) may be sending very bullish...

Yahoo | April 17, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!

William White on InvestorPlace | March 23, 2023

SQZ Biotech's Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

SQZ Biotechnologies Company (NYSE: SQZ) announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 trial. The second and third patients have also been enrolled in the trial. The company has completed the dose-limiting toxicity period for the lowest-dose cohort. The Study Safety Committee has completed its review and recommends that the company enroll patients in the highest dose cohort. The company anticipates initial c

Yahoo | March 23, 2023

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial. The second and third patients have also been enrolled in the trial. The company

Yahoo | March 22, 2023

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

Yahoo | March 22, 2023